Specialty Pharma Journal Specialty, Precision & Technology
BOTHELL, Wash.–(BUSINESS WIRE)–Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today announced a development and license agreement with Immunomedics, Inc. (Nasdaq: IMMU) under which Seattle Genetics would receive exclusive worldwide rights to develop, manufacture and commercialize sacituzumab govitecan (IMMU-132). Sacituzumab govitecan is an antibody-drug conjugate (ADC) targeted to TROP-2, …
Tag Archives: solid tumors
February, 2017
November, 2016
-
9 November
Bristol-Myers to Evaluate Opdivo in Combination with Infinity’s IPI-549 in Advanced Solid Tumors
CAMBRIDGE, Mass. and NEW YORK, Nov. 9, 2016 /PRNewswire/ — Bristol-Myers Squibb Company (NYSE: BMY) and Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced a clinical trial collaboration to evaluate Bristol-Myers Squibb’s Opdivo in combination with Infinity’s IPI-549 in patients with advanced solid tumors. The dose-escalation portion exploring IPI-549 as a …
April, 2016
-
18 April
Agena Bioscience Launches Genetic Testing Product for Targeted Analysis of Solid Tumors
SAN DIEGO, April 18, 2016 /PRNewswire/ — Today Agena Bioscience announced the commercial availability of iPLEX® HS, a new chemistry that enables highly sensitive, multiplexed detection of genetic variants present in solid tumors. iPLEX HS, unveiled today at the American Association of Cancer Research conference, provides cancer researchers a unique …
March, 2016
-
9 March
Molecular Therapy Highlights Sleeping Beauty Potential in Personalized TCR Gene Therapy
BOSTON, March 09, 2016 (GLOBE NEWSWIRE) — ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP), a biopharmaceutical company focused on new cancer immunotherapies, today announced the publication of an article describing the use of Sleeping Beauty non-viral gene transfer technology to modify T cells for the targeting of neoantigens present within solid tumors. This …
February, 2016
-
24 February
DNA ‘Trojan Horse’ Smuggles Drugs into Resistant Cancer Cells
COLUMBUS, Ohio–Researchers at The Ohio State University are working on a new way to treat drug-resistant cancer that the ancient Greeks would approve of–only it’s not a Trojan horse, but DNA that hides the invading force. In this case, the invading force is a common cancer drug. In laboratory tests, …
-
23 February
ImmunID and Memorial Sloan Kettering Partner to Validate Cancer Immunotherapy Companion Diagnostic
GRENOBLE, France, Feb. 23, 2016 /PRNewswire/ — ImmunID, the immune companion diagnostics for precision medicine company, today announces that it has just signed a master collaboration agreement with Memorial Sloan Kettering Cancer Center (MSK) in New York, United States. MSK is the world’s oldest and largest private cancer center. It has ranked …
January, 2016
-
5 January
New Blood Test Technology Promising for Guiding Treatment Decisions in Prostate Cancer
ALEXANDRIA, Va. – An early study suggests that an experimental new blood test may help guide individualized decisions on the most appropriate treatments for patients with prostate cancer. The new non-invasive “liquid biopsy” scans the entire landscape of different kinds of cancer cells in blood and analyzes their appearance (e.g., …
December, 2015
-
18 December
AstraZeneca to Acquire Majority Stake in Acerta Pharma in $4 Billion Deal
OSS, TheNetherlands & REDWOOD CITY, Calif.–(BUSINESS WIRE)–Acerta Pharma B.V. (Acerta), a clinical-stage biopharmaceutical company, announced today that it has entered into a definitive agreement with AstraZeneca whereby AstraZeneca will acquire a majority stake in Acerta. The transaction provides AstraZeneca with Acerta’s potential best-in-class irreversible oral Bruton’s tyrosine kinase (Btk) inhibitor, …